Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer
This case report presents a premenopausal patient with high-risk hormone receptor (HR)-positive, HER2-low breast cancer who underwent breast-conserving surgery and axillary lymph node dissection after neoadjuvant chemotherapy. Despite postoperative radiotherapy, the patient did not adhere to endocri...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1505354/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232167049723904 |
|---|---|
| author | Lingting Jiang Lingting Jiang Yingkuan Shao Qiang Chen Sifeng Tao |
| author_facet | Lingting Jiang Lingting Jiang Yingkuan Shao Qiang Chen Sifeng Tao |
| author_sort | Lingting Jiang |
| collection | DOAJ |
| description | This case report presents a premenopausal patient with high-risk hormone receptor (HR)-positive, HER2-low breast cancer who underwent breast-conserving surgery and axillary lymph node dissection after neoadjuvant chemotherapy. Despite postoperative radiotherapy, the patient did not adhere to endocrine therapy recommendations. Approximately five years later, metastases were identified in the liver, retroperitoneal lymph nodes, bones, and bladder. Notably, bladder metastasis, an exceptionally rare occurrence in breast cancer, was confirmed. Treatment with trastuzumab deruxtecan (T-DXd) demonstrated partial efficacy, though progression-free survival (PFS) was limited to six months. This case underscores the importance of vigilant follow-up and consideration of rare metastatic sites as breast cancer treatments evolve and improve. Bone-targeted therapies played a critical role, but the patient’s short PFS suggests significant tumor heterogeneity. This report discusses a rare case of bladder metastasis originating from HR-positive, HER2-low breast cancer, emphasizing innovative treatments such as T-DXd. |
| format | Article |
| id | doaj-art-ddc2b471f0474e949f16c0f49e1c416c |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ddc2b471f0474e949f16c0f49e1c416c2025-08-20T02:03:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15053541505354Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancerLingting Jiang0Lingting Jiang1Yingkuan Shao2Qiang Chen3Sifeng Tao4Department of Breast Surgery, Haiyan People's Hospital, Zhejiang, ChinaKey Laboratory of Cancer Prevention and Intervention, Ministry of Education, Department of Breast Surgery and Oncology, Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, ChinaKey Laboratory of Cancer Prevention and Intervention, Ministry of Education, Department of Breast Surgery and Oncology, Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, ChinaKey Laboratory of Cancer Prevention and Intervention, Ministry of Education, Department of Breast Surgery and Oncology, Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, ChinaKey Laboratory of Cancer Prevention and Intervention, Ministry of Education, Department of Breast Surgery and Oncology, Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, ChinaThis case report presents a premenopausal patient with high-risk hormone receptor (HR)-positive, HER2-low breast cancer who underwent breast-conserving surgery and axillary lymph node dissection after neoadjuvant chemotherapy. Despite postoperative radiotherapy, the patient did not adhere to endocrine therapy recommendations. Approximately five years later, metastases were identified in the liver, retroperitoneal lymph nodes, bones, and bladder. Notably, bladder metastasis, an exceptionally rare occurrence in breast cancer, was confirmed. Treatment with trastuzumab deruxtecan (T-DXd) demonstrated partial efficacy, though progression-free survival (PFS) was limited to six months. This case underscores the importance of vigilant follow-up and consideration of rare metastatic sites as breast cancer treatments evolve and improve. Bone-targeted therapies played a critical role, but the patient’s short PFS suggests significant tumor heterogeneity. This report discusses a rare case of bladder metastasis originating from HR-positive, HER2-low breast cancer, emphasizing innovative treatments such as T-DXd.https://www.frontiersin.org/articles/10.3389/fonc.2025.1505354/fullbladder metastasisHER2 low-expression breast cancerds8201aliver metastasisbone metastasis |
| spellingShingle | Lingting Jiang Lingting Jiang Yingkuan Shao Qiang Chen Sifeng Tao Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer Frontiers in Oncology bladder metastasis HER2 low-expression breast cancer ds8201a liver metastasis bone metastasis |
| title | Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer |
| title_full | Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer |
| title_fullStr | Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer |
| title_full_unstemmed | Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer |
| title_short | Case Report: Liver and bladder metastasis in a patient with HR-positive, HER2-low breast cancer |
| title_sort | case report liver and bladder metastasis in a patient with hr positive her2 low breast cancer |
| topic | bladder metastasis HER2 low-expression breast cancer ds8201a liver metastasis bone metastasis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1505354/full |
| work_keys_str_mv | AT lingtingjiang casereportliverandbladdermetastasisinapatientwithhrpositiveher2lowbreastcancer AT lingtingjiang casereportliverandbladdermetastasisinapatientwithhrpositiveher2lowbreastcancer AT yingkuanshao casereportliverandbladdermetastasisinapatientwithhrpositiveher2lowbreastcancer AT qiangchen casereportliverandbladdermetastasisinapatientwithhrpositiveher2lowbreastcancer AT sifengtao casereportliverandbladdermetastasisinapatientwithhrpositiveher2lowbreastcancer |